The acquisition includes Valencia, Calif.-based Bioness’ six-device portfolio of peripheral nerve stimulation therapy technology sold in 40 countries worldwide, according to a March 31 release.
Bioness systems are designed to help patients regain mobility after a stroke, traumatic brain injury, multiple sclerosis and osteoarthritis.
The total addressable market for Bioness medical devices is estimated to be more than $8 billion. In 2020, Bioness generated approximately $40 million in revenue.
More articles on devices:
Spinal fusion ‘picking up steam’ at ASCs: 2 leaders discuss practice growth
Alphatec, NuVasive & SeaSpine: Key spine acquisitions in 2021
Why endoscopic spine surgery in the US lags behind Europe, Asia
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.